beating alzheimer s and other degenerative brain diseases via a completely new approach read more we combine pioneering research and drug development read more our protein aggregation inhibitors aim to halt disease progression by targeting the underlying pathology of dementia read more protein aggregation inhibitor lmtx is a patented novel chemical entity currently in development for the prevention of alzheimer s and bvftd read more phase 3 trials for lmtx now completed over 1 900 patients across 20 countries read more toggle menu home about us science product pipeline clinical trials business development press room pioneering science the tau tangle pathway is a key driver of alzheimer s disease leading to loss of neuronal function spread of pathology and clinical symptoms . view alzheimer s innovations taurx s tau aggregation inhibitors are the outcome of nearly 30 years of research preclinical and clinical investigations . view clinicaltrials initial results from the first of taurx s two phase 3 trials in alzheimer s disease were presented at the 2016 aaic on 27th july . view september 2016 trx 237 007 phase 3 clinical aberdeen scotland and singapore 4th september 2016 taurx therapeutics ltd today announced that its read more july 2016 taurx reports first phase taurx therapeutics ltd today announced phase 3 clinical trial results that show treatment with lmtx read more july 2016 taurx phase 3 trial trx 237 007 taurx therapeutics ltd recently completed its phase 3 clinical trial of the company s second generation read more april 2016 regulators tell frontotemporal on april 1 in washington d.c. a meeting convened by the ftd treatment study group offered an assembly read more march 2016 a 30 year quest for alzheimer s after decades of researching a treatment for alzheimer s claude wischik is set to find out whether his read more view all home about us science product pipeline clinical trials business development press room copyright taurx 2016